[Theme Stocks] UXN, Continuous Blood Glucose Monitoring Device, Continually Receives Domestic and International Patent Approvals, Demonstrating Technical Strength

UXN Company has consecutively obtained patents for domestic and international continuous blood glucose monitoring device (CGMS) core technologies, further highlighting its technological competitiveness.

According to disclosures from the Korea Exchange announcement system, UXN has completed the registration of a domestic patent for “a continuous analyte measurement device with replaceable and reusable parts.” The core of this technology lies in a structure that separates the consumable parts containing sensors and batteries from the reusable parts containing electronic components. Designed to automatically supply power during use, it enhances convenience and simultaneously targets waterproof performance and device miniaturization.

Previously, the company also received a patent for an “implantable continuous blood glucose monitoring device” from the United States Patent and Trademark Office (USPTO). This technology is based on porous nano-electrodes containing metal nanoparticles, characterized by applying a non-DC voltage to achieve a self-cleaning function that removes foreign substances from the sensor surface. Additionally, it diagnoses sensor status in real-time and automatically calibrates sensitivity through electrochemical impedance spectroscopy, aiming to reduce performance degradation during in vivo implantation.

The market’s focus is not merely on increasing patents but on accumulating technology for commercialization. The patent for the separated structure emphasizes improving the usability and durability of wearable products, while the US patent focuses on enhancing the lifespan and stability of implantable sensors. This is why external expectations are that these innovations will boost the overall competitiveness of the next-generation CGMS products.

Previously, UXN has been engaged in the development of enzyme-free blood glucose sensors that replace glucose-sensitive enzymes with porous nano platinum. Since listing on the Kosdaq market in 2019, the company has developed its continuous blood glucose monitoring device business under the “AGMS™” brand, currently securing core technologies through 57 registered patents and 37 patent applications. This US patent is the company’s seventh US patent, with patent applications completed in five countries.

The company is also actively expanding into global markets. According to relevant background, it has signed a clinical trial business agreement with King Fahd University of Petroleum and Minerals in Saudi Arabia (KFU), and is preparing to enter confirmatory clinical trials after receiving innovative recognition from the Korean Ministry of Food and Drug Safety. The acquisition of this patent is expected to serve as a basis for enhancing technological credibility during future clinical trials and overseas business expansion.

According to data from the Korea Exchange, UXN’s stock price is 7,640 KRW. The stock name and code are UXN(337840), consistent with current market information.